Bedaquiline for multidrug-resistant TB in paediatric patients

BACKGROUND: TMC207-C211 ({"type":"clinical-trial","attrs":{"text":"NCT02354014","term_id":"NCT02354014"}}NCT02354014) is a Phase 2, open-label, multicentre, single-arm study to evaluate pharmacokinetics, safety/tolerability, antimycobacterial activity and dose selection of bedaquiline (BDQ) in children (birth to <18 years) with multidrug-resistant-TB (MDR-TB).